Targeting EV biogenesis or sorting mechanisms such as Rab27A inhibition or the interactions between CD63, LAMB1 and CD147 could provide novel therapeutic avenues to reverse resistance and re‐sensitize tumours to GCB. The gene discussed is CD63; the disease is neoplasm.